SANTA FE SPRINGS, Calif.--(BUSINESS WIRE)--Applied BioCode announced today that it has received U.S. Food and Drug Administration 510(k) clearance for the use of the Roche MagNA Pure 96* Extraction System with the high throughput BioCode® MDx-3000 and Gastrointestinal Pathogen Panel (GPP).
The BioCode® Gastrointestinal Pathogen Panel and BioCode® MDx-3000 System recently received U.S. Food and Drug Administration 510(k) clearance, using the bioMerieux NUCLISENS® easyMAG® extraction system. Now, with the addition of the MagNA Pure 96 System, Applied BioCode will have access to higher volume laboratories that utilize the Roche system for sample extraction. The MagNA Pure 96 System can extract DNA/RNA from up to 96 patient samples in approximately 60 minutes. The combination of the BioCode® MDx-3000 system and the Roche MagNA Pure 96 System will allow laboratories to easily process up to 188 patient samples in a single, 8-hour shift.
The comprehensive BioCode® Gastrointestinal Pathogen Panel provides results for the 17 most common bacteria, viruses, and parasites that cause infectious diarrhea. The panel includes targets for bacteria: Campylobacter (C. jejuni and C. coli), Clostridium difficile toxin A&B, Salmonella spp., Shigella/Enteroinvasive E. coli, Shiga-like toxin producing E.coli, E. coli O157, Enterotoxigenic E.coli, Enteroaggregative E. coli, Vibrio parahaemolyticus, Vibrio spp. (including Vibrio vulnificus and Vibrio cholerae), Yersinia enterocolitica, viruses: norovirus group I/II, adenovirus 40/41, rotavirus A, and parasites: Giardia lamblia, Cryptosporidium (C. hominis and C. parvum), Entamoeba histolytica.
The BioCode® MDx-3000 system offers the high volume laboratory an alternative to high cost, single use, cartridge-based molecular test systems. This user-friendly automated system also offers target masking capabilities within panels to address variation in test ordering patterns and potential changes in panel reimbursement. The BioCode® MDx-3000 system has the capability to process up to 3 different multiplex panels on the same run. It also offers a User Defined Mode where laboratories can develop their own multiplex assays to run on the system.
The BioCode® Gastrointestinal Pathogen Panel was the first of many syndromic infectious disease panels developed for the BioCode® MDx-3000 System. Applied BioCode also has a 20-plex Respiratory Pathogen Panel** completing Clinical Trials for the US market.
* The MagNA Pure 96 System is a product of F. Hoffmann-La Roche Ltd.
** In clinical trial, has not been cleared by the FDA.
About Applied BioCode, Inc.
Applied BioCode designs, develops, manufactures, and commercializes multiplex testing products. The company has combined “digital barcodes” with “immuno- and molecular chemistry” to create a new, bio-inspired Barcoded Magnetic Beads (BMB) technology. The micro BMB, with a diameter of human hair, is tagged with immunochemistry or molecular probes, allowing the digital barcode to be easily scanned and accurately identified for very high number (4,096 barcodes) of biological targets with no ambiguity. The company products focus on the molecular infectious disease segment of the market with assays that detect pathogens for gastrointestinal infections, respiratory infections, sexually transmitted infections, and others. Applied BioCode also partners with a variety of diagnostic companies with applications that include the infectious disease, autoimmune disease, allergy, gut microbiome, and veterinary markets. The BioCode® MDx-3000 system with GPP has obtained the CE-Mark for use in European countries, conforming to CE-Mark regulations, and is U.S. FDA cleared.